IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Amryt Pharma PLC - biopharmaceutical company focused on developing novel treatments for rare ...

Alliance News 14 September, 2021 | 6:32AM
Email Form Facebook Twitter LinkedIn RSS

Amryt Pharma PLC - biopharmaceutical company focused on developing novel treatments for rare diseases - Ups 2021 guidance to reflect the success of recent acquisition Chiasma Inc. Increases full-year revenue guidance to between USD220 million and USD225 million, representing growth of 20% to 23% on 2020. Previous guidance issued in August predicted revenue of between USD210 million and USD215 million, the company notes.

Chief Executive Joe Wiley says: "This latest upward revision of guidance demonstrates our confidence in the outlook for our underlying business and our visibility is further enhanced given that we have now begun the process of integrating Chiasma into Amryt and have begun to grow our combined business."

Current stock price: closed at 159.00 pence on Monday

Year-to-date change: down 16%

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Amryt Pharma PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures